The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery.

Recent advances in induced pluripotent stem cell technologies and phenotypic screening shape the future of bioactive small-molecule discovery. In this review we analyze the impact of small-molecule phenotypic screens on drug discovery as well as on the investigation of human development and disease biology. We further examine the role of 3D spheroid/organoid structures, microfluidic systems, and miniaturized on-a-chip systems for future discovery strategies. In highlighting representative examples, we analyze how recent achievements can translate into future therapies. Finally, we discuss remaining challenges that need to be overcome for the adaptation of the next generation of screening approaches.

[1]  Ali Khademhosseini,et al.  Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform , 2017, Scientific Reports.

[2]  Fengtang Yang,et al.  Human blood vessel organoids as a model of diabetic vasculopathy , 2019, Nature.

[3]  Fred Parham,et al.  Neurite outgrowth in human induced pluripotent stem cell-derived neurons as a high-throughput screen for developmental neurotoxicity or neurotoxicity. , 2016, Neurotoxicology.

[4]  M. Goumans,et al.  Phenotypic Screen for Cardiac Regeneration Identifies Molecules with Differential Activity in Human Epicardium-Derived Cells versus Cardiac Fibroblasts. , 2017, ACS chemical biology.

[5]  P. Schultz,et al.  Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis , 2017, Proceedings of the National Academy of Sciences.

[6]  R. Solé,et al.  The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.

[7]  Peter Reinhardt,et al.  Investigating human disease using stem cell models , 2014, Nature Reviews Genetics.

[8]  C. Antzelevitch,et al.  Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. , 2010, Current medicinal chemistry.

[9]  Jonathan S. Dordick,et al.  High-Throughput Toxicity and Phenotypic Screening of 3D Human Neural Progenitor Cell Cultures on a Microarray Chip Platform , 2016, Stem cell reports.

[10]  M. Somerman,et al.  Autotherapies: Enhancing Endogenous Healing and Regeneration. , 2018, Trends in molecular medicine.

[11]  Matthias Kretzler,et al.  High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping. , 2018, Cell stem cell.

[12]  Yu Zhang,et al.  Conversion of human fibroblasts into functional cardiomyocytes by small molecules , 2016, Science.

[13]  C. Regnault,et al.  Microfluidic Devices for Drug Assays , 2018, High-throughput.

[14]  Clive N. Svendsen,et al.  Human stem cells and drug screening: opportunities and challenges , 2010, Nature Reviews Drug Discovery.

[15]  C. I. Spencer,et al.  Expandable Cardiovascular Progenitor Cells Reprogrammed from Fibroblasts. , 2016, Cell stem cell.

[16]  M. Eisenstein.  Organoids: the body builders , 2018, Nature Methods.

[17]  Giulio Superti-Furga,et al.  Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study , 2017, The Lancet. Haematology.

[18]  David E James,et al.  Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest , 2017, Proceedings of the National Academy of Sciences.

[19]  Tom Misteli,et al.  High-Throughput Imaging for the Discovery of Cellular Mechanisms of Disease. , 2017, Trends in genetics : TIG.

[20]  G. Groothuis,et al.  Judging the value of ‘liver-on-a-chip’ devices for prediction of toxicity , 2017, Expert opinion on drug metabolism & toxicology.

[21]  Asher Mullard.  Microfluidics platform lowers barrier to drug combination screening , 2018, Nature Reviews Drug Discovery.

[22]  Ivan Rusyn,et al.  High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes , 2015, Assay and drug development technologies.

[23]  Arnold R. Kriegstein,et al.  The use of brain organoids to investigate neural development and disease , 2017, Nature Reviews Neuroscience.

[24]  Albert S. Yu,et al.  An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery. , 2016, Cell stem cell.

[25]  A. Brivanlou,et al.  Combined small-molecule inhibition accelerates the derivation of functional, early-born, cortical neurons from human pluripotent stem cells , 2017, Nature Biotechnology.

[26]  P. Selzer,et al.  How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice. , 2017, Assay and drug development technologies.

[27]  Dong-Woo Cho,et al.  3D Printing of Organs-On-Chips , 2017, Bioengineering.

[28]  K. Sekine,et al.  Massive and Reproducible Production of Liver Buds Entirely from Human Pluripotent Stem Cells. , 2017, Cell reports.

[29]  Xu Zhang,et al.  Direct Reprogramming of Fibroblasts via a Chemically Induced XEN-like State. , 2017, Cell stem cell.

[30]  Jiashun Zheng,et al.  Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation. , 2016, Cell stem cell.

[31]  Nick Barker,et al.  Organoids as an in vitro model of human development and disease , 2016, Nature Cell Biology.

[32]  T. Asada,et al.  iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease. , 2017, Cell reports.

[33]  Anne E Carpenter,et al.  Multiplex Cytological Profiling Assay to Measure Diverse Cellular States , 2013, PloS one.

[34]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[35]  Marc Bickle,et al.  Screening out irrelevant cell-based models of disease , 2016, Nature Reviews Drug Discovery.

[36]  M. Araúzo-Bravo,et al.  Rules governing the mechanism of epigenetic reprogramming memory. , 2018, Epigenomics.

[37]  Hoa Hue Truong,et al.  Chemical Conversion of Human Fibroblasts into Functional Schwann Cells , 2014, Stem cell reports.

[38]  Meera T Saxena,et al.  Three-dimensional automated reporter quantification (3D-ARQ) technology enables quantitative screening in retinal organoids , 2017, Development.

[39]  E. Wolvetang,et al.  Induction of Human iPSC-Derived Cardiomyocyte Proliferation Revealed by Combinatorial Screening in High Density Microbioreactor Arrays , 2016, Scientific Reports.

[40]  Bruce S. Edwards,et al.  Flow Cytometry , 2015, Journal of biomolecular screening.

[41]  Hans Clevers,et al.  Modeling Development and Disease with Organoids , 2016, Cell.

[42]  A. Weishaupt,et al.  Functional Connectivity under Optogenetic Control Allows Modeling of Human Neuromuscular Disease. , 2016, Cell stem cell.

[43]  Oksana Sirenko,et al.  Phenotypic Characterization of Toxic Compound Effects on Liver Spheroids Derived from iPSC Using Confocal Imaging and Three-Dimensional Image Analysis , 2016, Assay and drug development technologies.

[44]  Peter Ertl,et al.  Recent advances in microfluidic technologies for cell-to-cell interaction studies. , 2018, Lab on a chip.

[45]  Zhangxian,et al.  Linking phenotypes and modes of action through high-content screen fingerprints. , 2015 .

[46]  P. Loria,et al.  Developing predictive assays: The phenotypic screening “rule of 3” , 2015, Science Translational Medicine.

[47]  G. Drewes,et al.  Discovery of Novel Small Molecules that Activate Satellite Cell Proliferation and Enhance Repair of Damaged Muscle. , 2016, ACS chemical biology.

[48]  Š. Polák,et al.  Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells. , 2016, Canadian journal of physiology and pharmacology.

[49]  J. Bagley,et al.  Genetically engineered cerebral organoids model brain tumour formation , 2018, Nature Methods.

[50]  B. Soh,et al.  Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells , 2018, International journal of molecular sciences.

[51]  J. Steitz,et al.  The Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones , 2014, Cell.

[52]  Mei Ding,et al.  Application of High-Throughput Flow Cytometry in Early Drug Discovery: An AstraZeneca Perspective , 2018, SLAS discovery : advancing life sciences R & D.

[53]  E. Berg,et al.  Neoclassic Drug Discovery , 2013, Journal of biomolecular screening.

[54]  Valeria Orlova,et al.  Complex Tissue and Disease Modeling using hiPSCs. , 2016, Cell stem cell.

[55]  Kenneth J. Rothschild,et al.  Proteome-wide drug screening using mass spectrometric imaging of bead-arrays , 2016, Scientific Reports.

[56]  C. Antczak,et al.  Challenges and opportunities toward enabling phenotypic screening of complex and 3D cell models. , 2015, Future Medicinal Chemistry.

[57]  R. Gangnus,et al.  Potential and limitations of microscopy and Raman spectroscopy for live-cell analysis of 3D cell cultures. , 2015, Journal of biotechnology.

[58]  R. Harrison,et al.  Phase II and phase III failures: 2013–2015 , 2016, Nature Reviews Drug Discovery.

[59]  Ning Hu,et al.  Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors , 2017, Proceedings of the National Academy of Sciences.

[60]  Luke P. Lee,et al.  Human iPSC-based Cardiac Microphysiological System For Drug Screening Applications , 2015, Scientific Reports.

[61]  Yong Duan,et al.  A review of impedance measurements of whole cells. , 2016, Biosensors & bioelectronics.

[62]  M. Götz,et al.  Direct Neuronal Reprogramming: Achievements, Hurdles, and New Roads to Success. , 2017, Cell stem cell.

[63]  S. Lang,et al.  Small molecules increase direct neural conversion of human fibroblasts , 2016, Scientific Reports.

[64]  A. Kriegstein,et al.  Cerebral Organoids in a Dish: Progress and Prospects , 2013, Cell.

[65]  T. Enver,et al.  Forcing cells to change lineages , 2009, Nature.

[66]  Gordana Vunjak-Novakovic,et al.  Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development. , 2018, Cell stem cell.

[67]  Qisheng Zhang,et al.  High-Content Screening in hPSC-Neural Progenitors Identifies Drug Candidates that Inhibit Zika Virus Infection in Fetal-like Organoids and Adult Brain. , 2017, Cell stem cell.

[68]  Juergen A. Knoblich,et al.  Organogenesis in a dish: Modeling development and disease using organoid technologies , 2014, Science.

[69]  Paola Arlotta,et al.  Organoids required! A new path to understanding human brain development and disease , 2018, Nature Methods.

[70]  Joseph R Ecker,et al.  Cerebral Organoids Recapitulate Epigenomic Signatures of the Human Fetal Brain. , 2016, Cell reports.

[71]  T. Bouwmeester,et al.  High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome , 2015, Journal of biomolecular screening.

[72]  H. Schöler,et al.  Small-molecule phenotypic screening with stem cells. , 2017, Nature chemical biology.

[73]  Jürgen Winkler,et al.  Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects. , 2015, Cell stem cell.

[74]  John G. Moffat,et al.  Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.

[75]  J. Drews.  Genomic sciences and the medicine of tomorrow , 1996, Nature Biotechnology.

[76]  Michael L Shuler,et al.  Design and demonstration of a pumpless 14 compartment microphysiological system , 2016, Biotechnology and bioengineering.

[77]  Madeline A. Lancaster,et al.  Cerebral organoids model human brain development and microcephaly , 2013, Nature.

[78]  D. Pereira,et al.  Origin and evolution of high throughput screening , 2007, British journal of pharmacology.

[79]  Dharmendra Kumar,et al.  Clinical potential of human-induced pluripotent stem cells , 2017, Cell Biology and Toxicology.

[80]  V. Tabar,et al.  Retinoic Acid-Mediated Regulation of GLI3 Enables Efficient Motoneuron Derivation from Human ESCs in the Absence of Extrinsic SHH Activation , 2015, The Journal of Neuroscience.

[81]  Thomas Gasser,et al.  Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors for Neurodegenerative Disease Modeling , 2013, PloS one.

[82]  Hans R. Schöler,et al.  Small Molecule-Assisted, Line-Independent Maintenance of Human Pluripotent Stem Cells in Defined Conditions , 2012, PloS one.

[83]  Jennifer M. Bolin,et al.  Chemically defined conditions for human iPS cell derivation and culture , 2011, Nature Methods.

[84]  Hans Clevers,et al.  Disease Modeling in Stem Cell-Derived 3D Organoid Systems. , 2017, Trends in molecular medicine.

[85]  D. Huh,et al.  Organs-on-chips at the frontiers of drug discovery , 2015, Nature Reviews Drug Discovery.

[86]  A. Torkamani,et al.  Diverse reprogramming codes for neuronal identity , 2018, Nature.

[87]  Xavier Gidrol,et al.  Deciphering Cell Intrinsic Properties: A Key Issue for Robust Organoid Production. , 2017, Trends in biotechnology.

[88]  G. Wynne,et al.  Stemistry: the control of stem cells in situ using chemistry. , 2015, Journal of medicinal chemistry.

[89]  Ana Sofia Pina,et al.  An historical overview of drug discovery. , 2009, Methods in molecular biology.

[90]  C. Wiesmann,et al.  The discovery of first-in-class drugs: origins and evolution , 2014, Nature Reviews Drug Discovery.

[91]  Jiashun Zheng,et al.  Brown Adipogenic Reprogramming Induced by a Small Molecule. , 2017, Cell reports.

[92]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[93]  A. Martinez-Arias,et al.  The hope and the hype of organoid research , 2017, Development.

[94]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[95]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[96]  Jeremy L Jenkins,et al.  Identifying compound efficacy targets in phenotypic drug discovery. , 2016, Drug discovery today.

[97]  Jeff W. Lichtman,et al.  SnapShot: Tissue Clearing , 2017, Cell.

[98]  J. Irwin,et al.  Identifying mechanism-of-action targets for drugs and probes , 2012, Proceedings of the National Academy of Sciences.

[99]  Hang Lu,et al.  Three-dimensional models for studying development and disease: moving on from organisms to organs-on-a-chip and organoids. , 2016, Integrative biology : quantitative biosciences from nano to macro.

[100]  H. Schöler,et al.  iPS cell derived neuronal cells for drug discovery. , 2014, Trends in pharmacological sciences.

[101]  H. Kubo,et al.  Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[102]  U. Eggert.  The why and how of phenotypic small-molecule screens. , 2013, Nature chemical biology.

[103]  Raymond R. Tice,et al.  Comparative neurotoxicity screening in human iPSC-derived neural stem cells, neurons and astrocytes , 2016, Brain Research.

[104]  Sangeeta N Bhatia,et al.  A Biophysical Indicator of Vaso-occlusive Risk in Sickle Cell Disease , 2022 .

[105]  S. Pașca,et al.  The rise of three-dimensional human brain cultures , 2018, Nature.

[106]  Anne E Carpenter,et al.  Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes , 2016, Nature Protocols.

[107]  R. J. Weber,et al.  Dissecting the stem cell niche with organoid models: an engineering-based approach , 2017, Development.

[108]  K. Foster,et al.  Microfluidics with fluid walls , 2017, Nature Communications.

[109]  H. Su,et al.  Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications , 2018, Cell transplantation.

[110]  Hans Clevers,et al.  Organoids in cancer research , 2018, Nature Reviews Cancer.

[111]  D. Swinney.  The value of translational biomarkers to phenotypic assays , 2014, Front. Pharmacol..

[112]  Herbert Waldmann,et al.  Novel approaches to map small molecule-target interactions. , 2016, Bioorganic & medicinal chemistry.

[113]  S. Yamanaka,et al.  A decade of transcription factor-mediated reprogramming to pluripotency , 2016, Nature Reviews Molecular Cell Biology.

[114]  D. Ingber,et al.  Microfluidic organs-on-chips , 2014, Nature Biotechnology.

[115]  A. Plowright,et al.  Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. , 2017, Cell chemical biology.

[116]  David W. Nauen,et al.  Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure , 2016, Cell.

[117]  Sheng Ding,et al.  Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening , 2017, Stem cell reports.

[118]  I. Rusyn,et al.  High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. , 2014, Assay and drug development technologies.

[119]  Praveen Shukla,et al.  High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells , 2017, Science Translational Medicine.

[120]  Alexander Böcker,et al.  Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem-cell-based phenotypic assay. , 2012, Cell stem cell.

[121]  Boyang Zhang,et al.  Synergistic Engineering: Organoids Meet Organs-on-a-Chip. , 2017, Cell stem cell.

[122]  A. Bithell,et al.  2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling , 2018, Molecular Neurodegeneration.

[123]  Shinya Yamanaka,et al.  Induced pluripotent stem cell technology: a decade of progress , 2016, Nature Reviews Drug Discovery.

[124]  D. Srivastava,et al.  Chemical Enhancement of In Vitro and In Vivo Direct Cardiac Reprogramming , 2017, Circulation.

[125]  James M. Wilson.  A History Lesson for Stem Cells , 2009, Science.

[126]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[127]  Hossein Azizpour,et al.  Phenotypic Image Analysis Software Tools for Exploring and Understanding Big Image Data from Cell-Based Assays. , 2018, Cell systems.

[128]  Ye Fang,et al.  Three-Dimensional Cell Cultures in Drug Discovery and Development. , 2017, SLAS discovery : advancing life sciences R & D.

[129]  Wei Zheng,et al.  Pluripotent Stem Cell Platforms for Drug Discovery. , 2018, Trends in molecular medicine.

[130]  D. Ingber,et al.  Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.

[131]  F. Sams-Dodd,et al.  Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. , 2013, Drug discovery today.

[132]  H. Deng,et al.  A XEN-like State Bridges Somatic Cells to Pluripotency during Chemical Reprogramming , 2015, Cell.